recombinant flu vaccine
Selected indexed studies
- Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. (N Engl J Med, 2023) [PMID:38091531]
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. (MMWR Recomm Rep, 2024) [PMID:39197095]
- First recombinant flu vaccine approved. (Am J Health Syst Pharm, 2013) [PMID:23413157]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. (2023) pubmed
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. (2024) pubmed
- First recombinant flu vaccine approved. (2013) pubmed
- A novel vaccine adjuvant for recombinant flu antigens. (2009) pubmed
- Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection. (2024) pubmed
- Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. (2022) pubmed
- [Bird flu (avian influenza): applicable recombinant DNA techniques in research and vaccine development]. (2008) pubmed
- Recombinant hemagglutinin influenza vaccine provides broader spectrum protection. (2016) pubmed
- Recombinant Influenza Vaccine in Adults under 65 Years of Age. (2024) pubmed
- Recombinant Influenza Vaccine in Adults under 65 Years of Age. (2024) pubmed